Cargando…
P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429009/ http://dx.doi.org/10.1097/01.HS9.0000969388.24922.b0 |
| _version_ | 1785090608378937344 |
|---|---|
| author | Shadman, Mazyar Srivastava, Bhavini Patel, Sima Saifan, Chadi Salkar, Monika Emond, Bruno Gogna, Priyanka Manceur, Ameur Lafeuille, Marie-Helene Stephens, Deborah |
| author_facet | Shadman, Mazyar Srivastava, Bhavini Patel, Sima Saifan, Chadi Salkar, Monika Emond, Bruno Gogna, Priyanka Manceur, Ameur Lafeuille, Marie-Helene Stephens, Deborah |
| author_sort | Shadman, Mazyar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429009 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290092023-08-17 P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT Shadman, Mazyar Srivastava, Bhavini Patel, Sima Saifan, Chadi Salkar, Monika Emond, Bruno Gogna, Priyanka Manceur, Ameur Lafeuille, Marie-Helene Stephens, Deborah Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429009/ http://dx.doi.org/10.1097/01.HS9.0000969388.24922.b0 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Shadman, Mazyar Srivastava, Bhavini Patel, Sima Saifan, Chadi Salkar, Monika Emond, Bruno Gogna, Priyanka Manceur, Ameur Lafeuille, Marie-Helene Stephens, Deborah P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title | P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title_full | P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title_fullStr | P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title_full_unstemmed | P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title_short | P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT |
| title_sort | p621: real-world dosing patterns and time to next treatment for previously untreated patients with cll/sll with or without ibrutinib dose reduction following an adverse event |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429009/ http://dx.doi.org/10.1097/01.HS9.0000969388.24922.b0 |
| work_keys_str_mv | AT shadmanmazyar p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT srivastavabhavini p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT patelsima p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT saifanchadi p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT salkarmonika p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT emondbruno p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT gognapriyanka p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT manceurameur p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT lafeuillemariehelene p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent AT stephensdeborah p621realworlddosingpatternsandtimetonexttreatmentforpreviouslyuntreatedpatientswithcllsllwithorwithoutibrutinibdosereductionfollowinganadverseevent |